• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tango Therapeutics Inc. (Amendment)

    2/14/24 4:08:57 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    SC 13G/A 1 d772348dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Tango Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    87583X109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Master Fund, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Capital Advisors LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint Capital Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint GP, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN (Limited Partnership)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Southpoint GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO (Limited Liability Company)


    CUSIP No. 87583X109

     

     1   

     NAMES OF REPORTING PERSONS

     

     John S. Clark II

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     5,276,699

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     5,276,699

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,276,699

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.2%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    Item 1(a).

    Name of Issuer:

    Tango Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    201 Brookline Avenue, Suite 901

    Boston, MA 02215

     

    Item 2(a).

    Names of Persons Filing:

    The name of the persons filing this report (the “Reporting Persons”) are:

     

      (i)

    Southpoint Master Fund, LP

     

      (ii)

    Southpoint Capital Advisors LP

     

      (iii)

    Southpoint Capital Advisors LLC

     

      (iv)

    Southpoint GP, LP

     

      (v)

    Southpoint GP, LLC

     

      (vi)

    John S. Clark II

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    1114 Avenue of the Americas, 22nd Floor

    New York, NY 10036

     

    Item 2(c).

    Citizenship:

     

    Southpoint Master Fund, L.P.:    Cayman Islands
    Southpoint Capital Advisors LP:    Delaware
    Southpoint Capital Advisors LLC:    Delaware
    Southpoint GP, LP:    Delaware
    Southpoint GP, LLC:    Delaware
    John S. Clark II:    United States

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    87583X109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 101,989,696 outstanding shares of Common Stock as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2023.

    Shares reported herein are held by Southpoint Master Fund, LP for which Southpoint Capital Advisors LP serves as the investment manager and Southpoint GP, LP serves as the general partner. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP and Southpoint GP, LLC serves as the general partner of Southpoint GP, LP. John S. Clark II serves as the managing member of both Southpoint Capital Advisors LLC and Southpoint GP, LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    SOUTHPOINT MASTER FUND, LP

    By: Southpoint GP, LP, its General Partner

    By: Southpoint GP, LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT CAPITAL ADVISORS LP

    By: Southpoint Capital Advisors LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT CAPITAL ADVISORS LLC
    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT GP, LP

    By: Southpoint GP, LLC, its General Partner

    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    SOUTHPOINT GP, LLC
    By:  

    /s/ John S. Clark II

     

    John S. Clark II

    Managing Member

    JOHN S. CLARK II
    By:  

    /s/ John S. Clark II

      John S. Clark II, individually
    Get the next $TNGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    7/17/2024$19.00Buy
    Jefferies
    4/4/2024Overweight
    Cantor Fitzgerald
    2/12/2024$18.00Overweight
    Piper Sandler
    12/8/2023$16.00Buy
    B. Riley Securities
    10/20/2022$10.00Neutral → Buy
    H.C. Wainwright
    9/20/2021$25.00Outperform
    SVB Leerink
    9/7/2021$12.00Outperform
    Wedbush
    9/7/2021$20.00Outperform
    Wedbush
    More analyst ratings

    $TNGX
    SEC Filings

    See more
    • SEC Form S-3 filed by Tango Therapeutics Inc.

      S-3 - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 5:25:01 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Tango Therapeutics Inc.

      10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 7:10:32 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 7:06:40 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Financials

    Live finance-specific insights

    See more
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

      11/8/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed

      5/9/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      11/18/24 7:20:03 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

      4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 7:41:18 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 6:04:34 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. "Accumulating data continue to support TNG462 as the potent

      5/12/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Jefferies initiated coverage on Tango Therapeutics with a new price target

      Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

      7/17/24 8:01:05 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Tango Therapeutics

      Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight

      4/4/24 8:18:34 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Tango Therapeutics with a new price target

      Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00

      2/12/24 6:28:21 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Barry Douglas sold $16,369 worth of shares (5,330 units at $3.07), decreasing direct ownership by 7% to 66,014 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:21:04 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beckman Daniella sold $25,282 worth of shares (8,232 units at $3.07), decreasing direct ownership by 5% to 150,284 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:10:55 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Crystal Adam sold $43,866 worth of shares (14,283 units at $3.07), decreasing direct ownership by 8% to 158,210 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:08:43 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Tango Therapeutics Inc.

      SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/20/24 4:24:26 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/7/24 9:35:56 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      10/28/24 9:22:40 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care